Latest Ipilimumab Stories
Published in the Journal for ImmunoTherapy of Cancer, review offers recommendations for manufacturing, pre-clinical studies, and clinical trial designs of cancer immunotherapies Milwaukee,
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma.
Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.
A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology
Additional Data Released at ASCO Annual Meeting Shows More Promising Results for Immunotherapy as a Treatment Option in Melanoma Chicago, IL (PRWEB) June 02,
Treatment with ipilimumab can result in durable antitumor effects despite a low overall response rate in patients with advanced mucosal melanoma (MM). Richard D.
- Emitting flashes of light; glittering.